PHAXIAM Therapeutics Valuation
Is 0QSS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0QSS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0QSS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0QSS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0QSS?
Key metric: As 0QSS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0QSS's PS Ratio? | |
|---|---|
| PS Ratio | 7.4x |
| Sales | €2.14m |
| Market Cap | €15.92m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.7x |
| Enterprise Value/EBITDA | -1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0QSS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.6x | ||
PBX ProBiotix Health | 3.7x | n/a | UK£7.9m |
VRCI Verici Dx | 2.2x | 78.8% | UK£7.6m |
ONC Oncimmune Holdings | 13.6x | 105.1% | UK£16.5m |
APTA Aptamer Group | 6.9x | n/a | UK£6.0m |
0QSS PHAXIAM Therapeutics | 7.4x | 92.4% | €15.9m |
Price-To-Sales vs Peers: 0QSS is expensive based on its Price-To-Sales Ratio (7.4x) compared to the peer average (6.6x).
Price to Sales Ratio vs Industry
How does 0QSS's PS Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Sales vs Industry: 0QSS is good value based on its Price-To-Sales Ratio (7.4x) compared to the European Biotechs industry average (8x).
Price to Sales Ratio vs Fair Ratio
What is 0QSS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 7.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0QSS's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.60 | €5.10 +218.8% | 3.9% | €5.30 | €4.90 | n/a | 2 |
| Nov ’25 | €1.70 | €5.10 +200.7% | 3.9% | €5.30 | €4.90 | n/a | 2 |
| Oct ’25 | €1.73 | €5.10 +194.8% | 3.9% | €5.30 | €4.90 | n/a | 2 |
| Sep ’25 | n/a | €5.10 0% | 3.9% | €5.30 | €4.90 | n/a | 2 |
| Aug ’25 | €1.95 | €5.10 +161.5% | 3.9% | €5.30 | €4.90 | n/a | 2 |
| Jul ’25 | €2.17 | €5.10 +135.0% | 3.9% | €5.30 | €4.90 | n/a | 2 |
| Jun ’25 | n/a | €6.82 0% | 17.3% | €8.00 | €5.64 | n/a | 2 |
| May ’25 | n/a | €6.85 0% | 16.8% | €8.00 | €5.70 | n/a | 2 |
| Apr ’25 | n/a | €7.25 0% | 10.3% | €8.00 | €6.50 | n/a | 2 |
| Mar ’25 | €2.83 | €9.60 +239.8% | 16.7% | €11.20 | €8.00 | n/a | 2 |
| Feb ’25 | €3.71 | €9.60 +158.8% | 16.7% | €11.20 | €8.00 | n/a | 2 |
| Jan ’25 | €4.51 | €9.85 +118.4% | 13.7% | €11.20 | €8.50 | n/a | 2 |
| Dec ’24 | €4.11 | €9.85 +139.7% | 13.7% | €11.20 | €8.50 | n/a | 2 |
| Nov ’24 | €4.59 | €9.85 +114.6% | 13.7% | €11.20 | €8.50 | €1.70 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Regeneron Pharmaceuticals
US$81.2b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$753.98
7D
0.6%
1Y
-8.0%
Formycon
€882.8m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€50.00
7D
7.5%
1Y
-24.1%
hVIVO
UK£146.3m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.21
7D
-6.1%
1Y
3.4%